Compare UVE & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UVE | DBVT |
|---|---|---|
| Founded | 1990 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 957.6M | 948.8M |
| IPO Year | 1996 | 2014 |
| Metric | UVE | DBVT |
|---|---|---|
| Price | $37.94 | $15.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $40.00 | $32.04 |
| AVG Volume (30 Days) | 127.0K | ★ 272.5K |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.97% | N/A |
| EPS Growth | ★ 214.43 | 10.26 |
| EPS | ★ 1.88 | N/A |
| Revenue | ★ $1,603,915,000.00 | $5,636,000.00 |
| Revenue This Year | N/A | $35.04 |
| Revenue Next Year | $2.88 | $2,360.78 |
| P/E Ratio | $20.21 | ★ N/A |
| Revenue Growth | 5.48 | ★ 35.77 |
| 52 Week Low | $21.96 | $8.50 |
| 52 Week High | $41.96 | $26.19 |
| Indicator | UVE | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 53.27 | 33.66 |
| Support Level | $30.42 | $12.63 |
| Resistance Level | $38.62 | $17.42 |
| Average True Range (ATR) | 0.96 | 0.98 |
| MACD | 0.08 | -0.05 |
| Stochastic Oscillator | 83.90 | 3.63 |
Universal Insurance Holdings Inc is an insurance holding company. Through its subsidiaries, the company mainly offers property and casualty insurance and value-added insurance services. It develops, markets, and underwrites insurance products for consumers predominantly in the personal residential homeowners lines of business and performs all other insurance-related services for its primary insurance entities, including risk management, claims management, and distribution. The group offers the following types of personal residential insurance: homeowners, renters/tenants, condo unit owners, and dwelling/fire, through an independent agent network and online distribution channels across multiple states in the United States of America.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.